Clinical features and treatment outcomes of progressive uveal melanoma

Milda Rancelyte, Justinas Pamedys, Ruta Grigiene, Birute Brasiuniene

Abstract


Uveal melanoma (UM) is a rare malignant tumor that differs from cutaneous melanoma in terms of pathogenesis, clinical behavior, and treatment response. Despite treatment for the primary tumor, 50% of UM patients develop metastatic disease, with the liver being the most affected organ. Furthermore, UM responds poorly to chemotherapy and immune checkpoint inhibitors. We present a clinical case of a 58-year-old female patient who was diagnosed with right eye choroidal melanoma cT2aN0M0. For the treatment of the initial tumor, the patient received stereotactic radiotherapy. However, 11 months after the initial diagnosis, the disease had progressed to the liver. The patient underwent radiofrequency ablation of liver metastases, then as the UM progressed - anti-PD-1 immunotherapy with nivolumab and ipilimumab were prescribed for the first-line palliative systemic treatment, later chemotherapy with dacarbazine (5 cycles) as the second-line systemic treatment. Based on the FoundationOne®CDx findings and an overview of clinical trials data, the MEK inhibitor trametinib was prescribed as a third-line palliative treatment. The patient died due to cancerous intoxication, with overall survival (OS) of 28 months (∼2.33 years) and a progression-free survival (PFS) of 11 months (∼0.92 years) since the initial diagnosis. Treatment-related adverse events could have an impact on the general health condition of the patient.

Keywords


uveal melanoma; immunotherapy; targeted therapy; chemotherapy; next-generation sequencing

Full Text:

PDF

References


Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885. doi: 10.1016/j.ophtha.2011.01.040. PMID: 21704381.

Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. doi: 10.1038/s41572-020-0158-0. Erratum in: Nat Rev Dis Primers. 2022;8(1):4. PMID: 32273508.

Weis E, Shah CP, Lajous M, Shields JA, Shields CL. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol. 2006;124(1):54-60. doi: 10.1001/archopht.124.1.54. PMID: 16401785.

Hammer H, Oláh J, Tóth-Molnár E. Dysplastic nevi are a risk factor for uveal melanoma. Eur J Ophthalmol. 1996;6(4):472-474. doi: 10.1177/112067219600600423. PMID: 8997595.

Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J. Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol. 2004;49(4):419-428. doi: 10.1016/j.survophthal.2004.04.009. PMID: 15231397.

Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld N, Sauerwein W, Stang A. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology. 2009;116(2):340-348. doi: 10.1016/j.ophtha.2008.09.040. PMID: 19091418.

Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol Oncol Clin North Am. 2012;26(6):1169-1184. doi: 10.1016/j.hoc.2012.08.004. PMID: 23116575.

Robertson AG, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):151. PMID: 28810145; PMCID: PMC5619925.

Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol. 2008;4(5):629-636. doi: 10.2217/14796694.4.5.629. PMID: 18922120; PMCID: PMC2577578.

Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651-4659. doi: 10.1167/iovs.03-0538. PMID: 14578381.

Chen L. Ocular lymphatics: state-of-the-art review. Lymphology. 2009;42(2):66-76. PMID: 19725271; PMCID: PMC4725303.

Xie L, Yang Y, Shen J. Efficient inhibition of uveal melanoma via ternary siRNA complexes. Int J Pharm. 2020;573:118894. doi: 10.1016/j.ijpharm.2019.118894. PMID: 31765784; PMCID: PMC6954003.

Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93(8):1042-1046. doi: 10.1136/bjo.2008.153684. PMID: 19429579.

Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119-127. doi: 10.1016/j.ajo.2009.01.023. PMID: 19375060.

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology. 2015;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. PMID: 26140250; PMCID: PMC4485723.

Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370-1380. doi: 10.1093/annonc/mdz176. PMID: 31150059.

Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:91. doi: 10.3389/fonc.2020.00091. PMID: 32117745; PMCID: PMC7033582.

Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-289. doi: 10.6004/jnccn.2019.0013. PMID: 30865922.

Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230-5234. doi: 10.1167/iovs.08-2145. PMID: 18719078; PMCID: PMC2634606.

Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-1413. doi: 10.1126/science.1194472. PMID: 21051595; PMCID: PMC3087380.

Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30(2):102-109. doi: 10.1016/j.joco.2018.02.005. PMID: 29988936; PMCID: PMC6034168.

Petrausch U, Martus P, Tönnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond). 2008;22(8):997-1007. doi: 10.1038/sj.eye.6702779. PMID: 17384575.

Decatur CL, Ong E, Garg N, et al. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. JAMA Ophthalmol. 2016;134(7):728-33. doi: 10.1001/jamaophthalmol.2016.0903. PMID: 27123562; PMCID: PMC4966162.

Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561-568. doi: 10.1097/CMR.0000000000000575. PMID: 30664106; PMCID: PMC6887637.




DOI: http://dx.doi.org/10.22551/2023.39.1002.10251

Copyright (c) 2023 Milda Rancelyte, Justinas Pamedys, Ruta Grigiene, Birute Brasiuniene

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975